Document Detail

Serious adverse events and death associated with treatment using long-acting beta-agonists.
MedLine Citation:
PMID:  17085799     Owner:  NLM     Status:  MEDLINE    
Two very large, randomized, double-blind clinical trials performed in the United Kingdom and in the United States have suggested that addition of salmeteräE to usual asthma therapy is associated with a significant increase in the incidence of serious adverse events and asthma-related deaths compared with addition of albuterol or placebo to usual therapy in the same type of patients. These results prompted the United States Food and Drug Administration (FDA) to issue a stern warning regarding these potential adverse effects and to advise that long-acting beta-agonists (LABAs) should not used as first-line therapy for the treatment of asthma. Two potential explanations have been proposed for these unexpected adverse effects. It has been suggested that more than a direct pharmacological effect of LABAs, these adverse events result from inadequate concomitant use of inhaled corticosteroids in subjects treated with these medicines. However, a detailed analysis of the results of the two large trials did not provide definitive conclusions regarding the potential protective role of inhaled corticosteroids. A second explanation, which the author here considers more plausible, is that a small group of patients with asthma develop idiosyncratic responses to LABAs, and common or rare variants in the genes that encode for proteins associated with the pharmacological response to these medicines are strongly suspected to predispose for these unusual deleterious responses. Until the biological mechanisms involved are better understood, efforts should be made to confine the use of LABAs to those patients who really need them.
Fernando D Martinez
Related Documents :
12125499 - Long-term effect of tcm decoctions in treatment of nephrotic syndrome.
15477549 - Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-...
14722349 - Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. a review of eff...
19727839 - The use of low-dose cyclophosphamide followed by aza/mmf treatment in childhood lupus n...
11371659 - Intravenous immunoglobulin application following immunoadsorption: benefit or risk in p...
17642399 - The beneficial effects of xolair (omalizumab) as add-on therapy in patients with severe...
25439339 - Clinically significant fatigue after stroke: a longitudinal cohort study.
3548009 - Comparison of butorphanol tartrate and meperidine in moderate to severe renal colic.
10697159 - Implementation and evaluation of a clinical pathway for tram breast reconstruction.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical reviews in allergy & immunology     Volume:  31     ISSN:  1080-0549     ISO Abbreviation:  Clin Rev Allergy Immunol     Publication Date:    2006 Oct-Dec
Date Detail:
Created Date:  2006-11-06     Completed Date:  2007-02-01     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  9504368     Medline TA:  Clin Rev Allergy Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  269-78     Citation Subset:  IM    
Arizona Respiratory Center, University of Arizona College of Medicine, Tucson, AZ.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Agonists / adverse effects*
Albuterol / adverse effects,  analogs & derivatives
Asthma / drug therapy*,  mortality
Cause of Death*
Clinical Trials as Topic
Ethanolamines / adverse effects
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Ethanolamines; 18559-94-9/Albuterol; 2I4BC502BT/salmeterol; 5ZZ84GCW8B/formoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  beta2-Agonists at the Olympic Games.
Next Document:  Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothe...